Seliciclib

Drug Profile

Seliciclib

Alternative Names: CYC 202; R-roscovitine

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Cyclacel Pharmaceuticals
  • Developer Cedars-Sinai Health System; Cyclacel Pharmaceuticals; University Hospital, Brest; University of Newcastle upon Tyne
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Cell cycle protein inhibitors; Cyclin dependent kinase 9 inhibitors; Cyclin-dependent kinase 2 inhibitors; Cyclin-dependent kinase-activating kinase inhibitors; MCL1 protein inhibitors; MCL1 protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Cystic fibrosis; Nasopharyngeal cancer; Non-small cell lung cancer; Pituitary ACTH hypersecretion; Rheumatoid arthritis
  • No development reported Breast cancer; Solid tumours
  • Discontinued Glomerulonephritis; Haematological malignancies

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Solid-tumours(Combination therapy, Late-stage disease) in USA (PO, Capsule)
  • 06 Jun 2016 Efficacy, adverse events and pharmacodynamics data from a phase I trial in Solid tumours presented at the 52nd Annual Meeting of the American Society of Clinical Oncology (ASCO-2016)
  • 29 Jun 2015 Seliciclib licensed to ManRos Therapeutics for development in Cystic fibrosis
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top